Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow
- Powell says recent inflation data point to need to keep rates higher for longer
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Morgan Stanley (MS) earnings beat lifts stock
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
ImmunoGen Reports Financial Results for Quarter Ended September 30 and Reviews Business Highlights
October 28, 2016 6:30 AM EDTPhase 3 FORWARD I Trial of Mirvetuximab Soravtansine On Track to Begin before Year End
FORWARD II Trial Assessing Mirvetuximab Soravtansine Combinations with Avastin®, Carboplatin, Doxil®, and Keytruda® Ongoing
Strategic Review Completed to Strengthen Underlying Business and Drive Long-term Growth
Conference Call to be Held at 8:00am ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
